SCHEMBL5490478

SCHEMBL5490478

Cc1ccc(Nc2ncc3cc(-c4ccccc4C)ccc3n2)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.57
KDR P35968 5/20 0.57
JAK3 P52333 5/20 0.57
MAPK14 Q16539 5/20 0.57
CTSD P07339 1/20 0.47
BACE1 P56817 1/20 0.47
RAB9A P51151 2/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FGFR4 P22455 4/20 0.41
TRPA1 O75762 1/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494575 0.73 LCK (1.00) LCKKDRJAK3MAPK14CTSD
SCHEMBL5494577 0.73 LCK (0.69) LCKKDRJAK3MAPK14CTSD
SCHEMBL5491478 0.73 LCK (0.69) LCKKDRJAK3MAPK14CTSD
SCHEMBL4892563 0.73 CCND3 (0.56) JAK3LMNAMAPK1TSHRCYP2C19
SCHEMBL15443137 0.73 LRRK2 (0.56) RAB9AKMT2APTK2
SCHEMBL25583242 0.73 DDR2 (0.60) LCKKDRJAK3MAPK14FGFR4
SCHEMBL5492979 0.72 RIPK2 (0.64) LCKKDRJAK3MAPK14CTSD
SCHEMBL5492036 0.72 LCK (0.56) LCKKDRJAK3MAPK14CTSD
SCHEMBL14569053 0.72 RIPK2 (0.64) LCKKDRJAK3MAPK14CTSD
SCHEMBL14569050 0.72 LCK (0.56) LCKKDRJAK3MAPK14CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885KDR 1044/4885JAK3 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.